← Back to Home

DemeRx

Private
#Alcohol Use Disorder#Opioid Use Disorder#Substance Use Disorders#Neuroplasticity#CNS Drug Development

DemeRx is a clinical-stage biopharmaceutical company developing ibogaine-derived therapeutics for substance use disorders and other CNS conditions. Its lead candidate DMX-1001 is an oral noribogaine formulation designed to retain the anti-addiction properties of ibogaine while improving cardiac safety and pharmacokinetic control. The company is launching the first U.S. clinical trial of an ibogaine-derived candidate, advancing a long-controversial psychedelic mechanism into modern clinical development.

Company Info

Sector: Biotechnology / CNS (Psychedelic-Derived Therapeutics)
Headquarters: Fort Lauderdale, Florida, USA
Founded: 2010
Website: www.demerx.com/
Funding Round: Venture-backed (multiple private rounds)
Total Funding: Undisclosed venture-backed funding

Funding & Investor Relations

IPO Outlook / Plans

None publicly disclosed; private clinical-stage biopharma.

Upcoming Milestones & Key Dates

2026
Clinical Trial

First U.S. clinical trial readout of DMX-1001 in Alcohol Use Disorder

H2 2026
Regulatory

FDA Type B meeting on broader DMX-1001 development plan

Clinical Development Pipeline

DMX-1001 (oral noribogaine)

Target: Noribogaine / serotonin and opioid receptor pharmacology (neuroplasticity)
Alcohol Use Disorder
Preclinical
Phase 1
Phase 2
Phase 3
Approved

DMX-1001 (oral noribogaine)

Target: Noribogaine / serotonin and opioid receptor pharmacology
Opioid Use Disorder
Preclinical
Phase 1
Phase 2
Phase 3
Approved

DMX-2000 series

Target: Ibogaine-derived analogs with improved safety
Additional CNS indications (undisclosed)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

To be confirmed

Founder and Chief Executive Officer

To be confirmed

Chief Medical Officer

To be confirmed

Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →